High-grade serous ovarian cancer (HGSOC) likely originates from the fallopian tube (FT) epithelium. 27
Introduction 40
High-grade serous ovarian cancer (HGSOC), an occult malignancy which is diagnosed in more than 41 230,000 women each year (Ferlay et al., 2015) , represents a major clinical challenge. Aside from the 42 difficulties in developing new lines of targeted treatments, late detection and lack of understanding of 43 the molecular mechanisms that drive development of the disease remain major hurdles. Studies in 44 BRCA1/2 germline mutation carriers undergoing prophylactic cancer risk-reducing surgery (Callahan et 45 al., 2007; Leeper et al., 2002) identified distinct early malignant changes in the distal part of the FT, 46 leading to wide-spread acceptance of the theory that the FT is the primary tissue of origin of HGSOC 47 5 addition, sustained inhibition of BMP signalling by Noggin (N) seems to be detrimental, as removal of 108 inhibitor was a prerequisite for successful cultivation in 13/15 HGSOC samples, indicating 109 fundamentally different roles of BMP and Wnt signalling in the regulation of stemness in HGSOC 110 compared to normal tissue. In summary 11/15 cultures could be initiated and expanded in medium 111 containing EGF, ROCK and TGF-β inhibitor, but without Noggin -thus allowing endogenous BMP 112 signalling. 5 of these 11 samples benefited from the addition of BMP2 for organoid formation, further 113 amplifying BMP signalling (B) . As this patient-dependent effect of BMP2 addition was always neutral 114 or positive, BMP2 was subsequently included in the standard medium composition. Therefore, the 115 combination of EGF and BMP2, together with the common components of the organoid cultures 116 ROCK,TGF-β inhibitor B27, N2 and nicotinamide was termed ovarian cancer medium (OCM). 117
Successfully established long-term HGSOC organoid cultures were passaged at a ratio of 1:2 to 1:3 118 every 10-20 days for at least 5 months prior to cryopreservation. Six lines were kept in culture for >1 119
year ( Supplementary Table 2 ). Thawed cancer organoids could routinely be expanded to a multi-well 120 screening format, and are thus suited for generating live biobanks of HGSOC organoids to explore 121 individual therapeutic options in vitro. 122
Immunofluorescence labelling confirmed that the organoids exhibit all hallmarks of an HGSOC 123 phenotype, including disorganized tissue architecture and loss of polarity (as marked by the absence 124 of a central cavity), an epithelial secretory identity of all cells (strong EpCAM and PAX8 expression), 125 and pleomorphic nuclei ( Fig. 1D ). HE staining further confirmed their morphological similarity to the 126 matching tissue samples (Fig. 1E ). Moreover, as proof-of-concept of the applicability of HGSOC 127 organoids for translational research, we tested the in vitro drug response to carboplatin, the major 128 first-line chemotherapeutic agent for HGSOC. As expected, organoids underwent cell death in a 129 concentration-dependent manner, with prominent differences between organoids from different 130 donors confirming individual variation in drug response among patients ( Fig. 1F and Supp. Fig. 1B) . 131
132

HGSOC organoids match tumor tissue in mutational profile and expression of biomarkers. 133
To test whether patient-derived organoid cultures correspond to the individual mutational profile of 134 the parental tumor, we performed targeted sequencing for 121 candidate genes that were selected 135 on the basis of previously published studies of ovarian cancer genomic profiles ( Supplementary Table  136 3) (Cancer Genome Atlas Research Network, 2011; Norquist et al., 2018) . Mutational analysis of 10 137 paired tumor fragments and organoids from 9 different patients revealed that despite the long-term 138 expansion in vitro, they retained a high level of similarity, even including allelic frequency ( Fig. 2A and 139 Supplementary Table 4 ). TP53 mutations were detected in the vast majority of samples (9/10), in 140 agreement with the almost universal occurrence of mutated p53 in HGSOC patients (Cancer Genome 141 6 Atlas Research Network, 2011). All of the TP53 mutations in the organoid cultures were homozygous 142 (<0.9 allele frequency), yet diverse with respect to mutation type (missense, nonsense, frame-shift or 143 splice variant mutations). In addition to somatic mutations with proven tumorigenic potential, a 144 number of known variant alleles were identified, including ROCK2 (c.1292C>A), KIT (c.1621A>C), MLH1 145 (c.655A>G) and MSH6 (c.472C>T) which could potentially influence malignant phenotype (Brahmi et 146 al., 2015; Kalender et al., 2010; Nakamura et al., 2014) . Apart from TP53, MLH1 and MSH6, we also 147 found point mutations in other genes with functions in DNA repair and chromosome stability, including 148 ATM (c.4534G>A), ATR (c.1517A>G), BRIP1 (c.254T>A) and FANCA (c.1238G>T). Interestingly, while no 149 classic germline or somatic BRCA1/2 mutations were detected apart from three polymorphisms that 150 are weakly associated with ovarian cancer (c.4900A>G, c.3113A>G, c.2612C>T), analysis of protein 151 lysates revealed a significant reduction compared to healthy FT organoids in 3 of 8 cases (OC4, OC2 152 and OC3; Suppl. Fig. 2A ). This strongly suggests the existence of epigenetic, or post-transcriptional 153 mechanisms of BRCA1 inactivation in these cases. Altogether, 7/9 patients had mutations in one or 154 more DNA repair gene, in congruence with the fact that HGSOC is a cancer characterized by a 155 particularly high incidence of genomic instability. Given our finding that HGSOC organoids could not 156 be maintained in the presence of Wnt, we noted with interest that 3 missense mutations in Wnt 157 pathway genes (Fzd9, LRP5, TCF7L2) were identified in 3 different patients ( Fig. 2A ), which could impair 158 signal transduction and thus provide further evidence that changes in this pathway play an important 159 role in ovarian carcinogenesis. Complementary to the sequencing data, WB and IF staining were 160 performed to examine the mutational status and subcellular localization of p53 in the organoids 161 ( Supplementary Table 4 ). While the nonsense mutation in OC11 as well as the splice variant and frame-162 shift mutations in OC4 and OC7, respectively, result in loss of p53 ( Fig. 2B and Supplementary Table 5) To more thoroughly evaluate parallels between tissue and organoid cultures, a global gene expression 167 analysis was performed from 8 different tumor/organoid pairs as well as 3 healthy FT tissue/organoid 168 pairs and 2 FT organoids derived from cancer patients (also classified as normal healthy tissue). The 169 generation of a multi-dimensional-scaling plot (MDS) revealed that the distance between OC and FT 170 organoids is smaller than between corresponding tissues, likely due to the greater complexity of tissue 171 samples, which contain mesenchymal and endothelial components ( Fig. 2D ). Still, despite the tissue 172 heterogeneity, the respective OC organoids express very similar levels of the main cancer markers, like 173 CDKN2A (p16), Muc16 and EpCAM, when compared to the parental sample ( Fig. 2E ). Moreover, 174 correlation analysis of FT and OC organoids (Supp. Fig. 2B ) shows that FT samples form a homogenous 7 cluster and show less variability in gene expression between each other than OC organoids, which 176 instead reflect the phenotypic diversity of ovarian tumors. 177 A thorough analysis of gene expression revealed that numerous hallmark genes known to be de-178 regulated in HGSOC are differentially expressed between OC and normal FT samples, not only in the 179 tissue but also in organoids ( Fig. 2F ). This includes significant up-regulation of the cell cycle regulators 180 CDKN2A and Cyclin E1 (CCNE1) and the transcription factor FOXM1, as well as down-regulation of 181 differentiation markers like PGR and OVGP1. 182
The strong up-regulation of CCNE1 was validated by western blot analysis in 5 out of 8 samples tested 183 (Supp. Fig. 2C and D), while RB protein itself, which is phosphorylated by CCNE1 to promote G1/S 184 progression, was not differentially expressed (data not shown). This indicates potential RB pathway 185 disruption by increased CCNE1 levels. Amplification of CCNE1 gene is common in HGSOC (~20-30% of 186 cases) but increased levels could also be a result of alternative signalling perturbations. 187
Together these results demonstrate that the patient-derived OC organoid lines are valid in vitro models 188 of the parental HGSOC tumors, resembling not only the tissue architecture but also the mutational 189 profile and overall gene expression. 190
191
Stable triple knockdown of p53, PTEN and RB in FT organoids 192
In the next step, we wanted to analyze at which stage of disease development the observed changes 193 in niche factor requirements occur. This is a question of particular importance in HGSOC, where 194 transformation appears to occur in the FT but cancers are very rarely detected at this site. To mimic 195 the cellular events, like mutation of p53 and loss of PTEN, which characterize the early stages of 196 malignant transformation in vitro, we used organoids from healthy FT donor epithelium. In contrast to 197 previous tumorigenesis models based on the transformation of immortalized primary FT monolayers 198 (Jazaeri et al., 2011; Nakamura et al., 2018) , organoids are genomically unaltered and have preserved 199 epithelial polarity and integrity, thus ensuring mucosal homeostasis. 200 In order to model HGSOC development, shRNAs against p53, PTEN, and RB -the major known tumour 201 drivers of the disease -were introduced into healthy human FT epithelial cells from donor tissues 202 obtained during surgeries for benign gynecological conditions. The shRNAs were delivered sequentially 203 by retro-and lentiviral vectors into epithelial cells grown in 2D culture, selected by FACS (shPTEN-204 mCherry, shRB-GFP) and subsequently transferred to Matrigel to initiate organoid formation ( Fig. 3A  205 and Suppl. Fig. 3A ). Among the double-positive mCherry/GFP population (shPTEN, shRB), p53 depleted 206 organoids were selected with puromycin. Successful knockdown of all 3 target genes was confirmed 207 on RNA as well as protein level (Fig. 3B ). In total 7 triple knockdown (KD) cultures were successfully 208 8 generated from different FT donor tissue confirming robustness of the methodology (Suppl. Fig. 3D ). 209
In congruence with the downregulation of RB and PTEN protein, functional analysis of triple KD 210 organoids revealed an increase in expression of CCNE1 ( Fig. 3C ) and elevated levels of activated 211 phosphorylated Akt (pAkt), respectively (Suppl. Fig. 3B ). Depletion of p53 protein was confirmed by 212 resistance of organoids to the MDM2 inhibitor Nutlin3A, which triggers apoptosis in p53 WT cells 213 (Suppl. Fig.3C ). 214
We next compared phenotypes of KD and WT organoids by confocal microscopy. We observed loss of 215 cell shape and misalignment of the nuclei, indicative of changes in the maintenance of apico-basal 216 polarity -although the organization of the monolayer remained intact and the lumen was preserved 217 with a cystic growth of the organoids. Triple KD cells also showed a stronger signal for the DNA damage 218 marker yH2AX, indicating an increased frequency of DNA double-strand breaks and thus suggesting 219 genomic instability ( Fig. 3D ). Notably, KD organoids had enlarged and polymorphic nuclei, which is one 220 of the prominent morphological characteristics of HGSOC cells ( Fig. 3D ). While all these phenotypic 221 changes suggest that the knockdown of p53, PTEN, and RB in FT organoids is pro-carcinogenic, none is 222 sufficient as bona fide evidence of malignancy. Indeed KD cells remained competent to undergo 223 differentiation into ciliated cells, which are thought to be the terminally differentiated cells of the FT 224 ( Fig. 3E ). 225 226
Rescue of KD organoid lines in ovarian cancer medium 227
Despite an initial growth advantage until the first passage after seeding, KD organoids cannot be 228 maintained in long-term culture and undergo growth arrest after 4-8 passages, as shown by the growth 229 curve in comparison to WT and vector control ( Fig. 4A and Suppl. Fig. 4A ). While individual differences 230 among different donor cultures were observed, the premature growth arrest of KD organoids was 231 confirmed in 7/7 cases (Suppl. Fig. 3D ). This suggests that the KD organoids may undergo similar 232 changes in stemness regulation as those observed in the HGSOC organoids. 233
Indeed, growing the organoids in ovarian cancer medium improved organoid formation efficiency and 234 enabled long-term growth (Fig. 4B ). Importantly, long-term growth could only be rescued if OCM was 235 added at passage 0/1, suggesting that inadequate niche conditions lead to irreversible loss of 236 stemness. Phase contrast images (Suppl. Fig. 4B ) confirm that while individual organoids grow to a 237 similar size, organoid numbers are lower at each passage in FTM, finally resulting in premature growth 238 arrest. Western blot analysis of γH2AX and cleaved caspase 3, as well as PARP1, indicated that the 239 growth-suppressive effect of Wnt3a did not result from direct cytotoxicity, as DNA damage and 240 apoptosis was not reduced when organoids were grown in OCM ( Fig. 4C and Supp. Fig. 4C ). Single p53 241 or double p53/PTEN KD on the other hand did not exhibit increased γH2AX levels, irrespective of the 242 9 medium used, indicating that the enhanced DNA damage observed in triple KDs is the result of RB 243 depletion. 244
In order to discover factors induced by culture in OCM that contribute to maintenance of stemness 245 and longevity of the triple KD and HGSOC organoids, we performed global gene expression analysis. As 246 expected, OCM medium devoid of Wnt and RSPO1 led to a reduction in the expression of Wnt target 247 genes in both organoids (Suppl. Fig. 4D ). The microarray data also reveal that despite cell growth arrest 248 of the KD organoids in FTM, they continue to show elevated expression of classical HGSOC markers, 249 including FOXM1, TOP2A, CDKN2A, and WT1, albeit at lower levels than when grown in OCM ( Fig. 4D) . 250
This finding proves that knockdown of key tumor suppressor genes is sufficient to induce a degree of 251 cellular transformation towards a cancer phenotype and supports the view that the FT epithelium is 252 the tissue of origin of HGSOC. To substantiate these results, we analyzed the direct effect of Wnt3a/RSPO1 supplementation on 280 patient-derived HGSOC organoid growth and CD133 expression. Differential treatment of cancer 281 organoids over 2 passages clearly showed that addition of these Wnt agonists to OCM resulted in a 282 highly significant (p < 0.0001) inhibition of organoid growth, an effect confirmed for all 6 OC organoid 283 lines tested ( Fig. 5C ). Interestingly, the inhibitory effect of noggin on already established cultures was 284 mild, but significant, confirming that BMP pathway activity is beneficial for growth but not as essential 285 as for initial organoid formation. However, addition of noggin to mature organoid lines had no effect 286 on the number of CD133+ cells, while Wnt3a/RSPO1 reduced numbers significantly ( Fig. 5D and Supp. 287 As Wnt3a supplementation relies on the addition of conditioned medium from a Wnt-producing cell 290 line, we next wanted to confirm that its effect was specific to the presence of Wnt. Indeed, Wnt-291 conditioned medium strongly upregulated the established Wnt target gene AXIN2 (Suppl. Fig. 5C ). In 292 addition, medium conditioned by the parental cell line without the Wnt-producing vector (CM) did not 293 negatively affect organoid growth ( Fig. 5E ). 294
Overall, it can be concluded that the presence of Wnt ligands, which induce a signature of canonical 295 Wnt target gene expression in KD and HGSOC organoids, results in a striking decrease of stemness and 296 growth capacity in these cultures. 297
298
MYCN and Wnt inhibitors are upregulated in HGSOC and KD FT organoids 299
The data from HGSOC organoids provide strong evidence that the mechanisms by which growth of 300 cancer organoid stem cells is maintained are altered from those in the healthy epithelium and our 301 experiments with KD organoids further show that depletion of only three tumor-driver genes can 302 recapitulate this effect. To get a better insight into putative candidate genes that could contribute to 303 the maintenance of stemness in cancer organoids, we compared microarray data of healthy FT 304 epithelium and HGSOC tissue as well as patient-derived cancer and KD organoids grown in OC vs FT 305 medium (Fig. 6A ). The proto-oncogene MYCN was uniformly upregulated in cancer tissue, as well as 306 triple KD organoids cultured in OCM, suggesting that it may play a role in driving stemness and cancer 307 growth in HGSOC. qPCR confirmed MYCN expression to be significantly higher in cancer organoids 308 compared to FT organoids ( Fig. 6B , left panel). In addition, expression levels of MYCN relative to GAPDH 309 11 were validated by qPCR in 3 independent biological replicates of triple KD organoids cultured in OCM 310 vs. FTM ( Fig. 6B, right 
panel). 311
In line with our finding that suppression of canonical Wnt signaling supports the growth of cancer 312 organoids, the gene expression data revealed enhanced expression of the Wnt inhibitors KREMEN2 313 and DKK3 in both triple KD and OC organoids ( Fig. 6A ). While KREMEN2 regulation appears to be driven 314 by changes in the genetic background, DKK3 expression seems to be induced by Wnt-free medium. 315
Therefore, it appears that the altered paracrine signaling environment further promotes inhibition of 316 canonical Wnt signaling. Interestingly, downregulation of p53/PTEN/RB in FT organoids caused a 317 decrease in Wnt target gene expression even in the presence of Wnt3a and RSPO1 (Fig.6C ), while 318 culture in Wnt-free medium leads to a further strong reduction of LEF1 and TCF transcripts down to 319 the detection limit of the microarray (see Supplementary Table 6 ). The expression of Wnt inhibitors 320 and the reduced Wnt signaling induced by tumor suppressor KD are in agreement with our hypothesis 321 that Wnt pathway suppression is required for HGSOC growth. Interestingly, HGSOC organoids 322 expressed increased levels of differentiation markers when exposed to Wnt3a/RSPO1. In line with the 323 microarray results and data from the triple KD organoids, RT-PCR confirmed increased expression of 324 the ciliogenesis factor FOXJ1 in cancer organoids cultured in the presence of Wnt3a/RSPO1 (Fig. 6D) . 325
Based on this, we postulate a two-step process of HGSOC development in which changes in the niche 326 environment are a necessary step that drives dedifferentiation and maintains stemness in cells bearing 327 tumorigenic mutations. Our analysis of HGSOC and KD organoids clearly demonstrates that a high Wnt environment leads to 360 the downregulation of stemness genes and the upregulation of differentiation genes. Mouse lineage 361 tracing data previously showed that active Wnt signaling is required both for renewal of Pax8 secretory 362 cells and their differentiation to ciliated cells (Ghosh et al., 2017) . Our data strongly suggest that the 363 regulation of these processes becomes separated during carcinogenesis. While Wnt stimulation still 364 13 induces differentiation and ciliogenesis in cancer organoids, it inhibits stemness and expansion 365 capacity. The same effect is observed in triple KD organoids, indicating that depletion of key tumor 366 driver proteins is sufficient to induce these alterations in stem cell regulation. Yet, despite the change 367 in growth requirements, the prominent occurrence of nuclear atypia, increase of DNA damage and 368 changes in epithelial organization, triple KD organoids maintained key elements of epithelial polarity. 369
Therefore, it appears they have not completed the process of transformation and that additional 370 changes are needed for malignancy to develop. This is also in line with the observation that growth 371 rescue in OCM medium was incomplete. Unlike the stable long-term expansion of HGSOC organoids, 372 which were routinely cultured for over 1 year without changes in growth dynamics, the lifespan of KD 373 organoids in OCM was limited to 7-8 months. progenitors, the tissue pieces were washed with DPBS, minced with a scalpel into very small pieces 575 and incubated in a 1:1 mixture of collagenase I and II (Sigma) for around 60 min at 37°C on a shaker. 576
Afterwards, the enzyme-tissue mixture was vortexed to further separate the cells. Next, the cell 577 suspension was centrifuged (5 min, 300 x g, 4°C), resuspended in ADF+++ supplemented with 578 Pen/Strep, hEGF and ROCK inhibitor and seeded in a cell culture vessel or directly in Matrigel TM . 579 580
Organoid culture of FT epithelial cells (FTECs) 581
The organoids were cultured as described in Kessler et al (2015) . In brief, to initiate organoid growth 582 approximately 30,000 cells obtained from 2D culture, were seeded in 50 µL Matrigel TM and overlaid 583 with a growth factor cocktail stimulating different paracrine pathways including EGF and Wnt 584 signalling. The composition for normal FT epithelial cell medium (FTM) was as follows: ADF, 25% 585 conditioned Wnt3A-medium and 25 % conditioned RSPO1 medium, supplemented with 12 mM HEPES, 586 1% GlutaMAX TM , 2% B27, 1% N2, human EGF, human noggin, human FGF-10, 1 mM nicotinamide, 9 587 µM ROCK inhibitor (Y-27632) and 0.5 µM TGF-β RI Kinase Inhibitor IV (SB431542). 588 20 Medium was changed every 3-4 days and organoids were expanded every 2-3 weeks at a rate of 1:2 589 to 1:3. To do so, organoids were released from Matrigel TM , washed with ADF++, taken up in pre-590 warmed TrypLE TM and incubated for 7-10 min at 37 °C for enzymatic digestion. Subsequently, organoids 591 were vortexed, washed with ADF++ and pelleted. Finally, the shredded organoids were resuspended 592 in fresh Matrigel TM and seeded into pre-warmed cell culture plates before FTM was added to the 593 organoids. 594 595
Organoid culture of ovarian cancer cells 596
After initial isolation from the tumor tissue, ovarian cancer cells were seeded in Matrigel TM at a 597 concentration of approx. 30,000 cells/50 µl. Because cancer cells did not form organoids or were 598 difficult to expand in FTM, different media compositions were tested to support in vitro growth. The 599 basic medium for the ovarian cancer organoids always contained the following supplements and 600 growth factors: ADF supplemented with 12 mM HEPES, 1% GlutaMAX TM , 2% B27, 1% N2, human EGF, 601 1 mM nicotinamide, 9 µM ROCK inhibitor (Y-27632) and 0.5 µM TGF-β RI Kinase Inhibitor IV 602 (SB431542). Upon proper organoid maturation and growth under specified conditions they were split 603 at a ratio of 1:3 every 1-2 weeks. To expand the OC organoids they were released from Matrigel TM 604 using ice-cold ADF++, centrifuged and resuspended in pre-warmed TrypLE TM . Enzymatic digestion was 605 carried out for 7 min at 37 °C. Afterwards, the organoid suspension was vortexed, mixed with cold 606 ADF++ and centrifuged (300xg, 5 min). Next, the supernatant was removed, the cell pellet resuspended 607 in Matrigel TM and seeded into pre-warmed cell culture plates. After ~20 min the Matrigel TM was 608 overlaid with the respective medium. The medium was changed twice per week and the organoids 609 kept in a humidified incubator at 37 °C and 5% CO2. 610 21 611
Organoid stocks 612
Organoid stocks were prepared by releasing organoids from ~1 week-old confluent cultures in cold 613 ADF++, pelleting by centrifugation and resuspension in the freezing medium CryoSFM. After transfer 614 Table  805 3). Capture was performed according to the manufacturer's instructions using an NGS Workstation 806 Option B (Agilent) for automated library preparation starting with 3 µg DNA per sample. Sequencing 807 was performed on an Illumina HiSeq 2500 system generating 2x100bp paired end reads with a target 808 coverage of >200-fold per sample. Sequence reads were mapped to the haploid human reference 809 genome (hg19) using BWA. Single nucleotide variants (SNVs) and short insertions and deletions (indels) 810 were called using FreeBayes v1.1. (Garrison and Marth, 2012) . 811
Variants called by FreeBayes were filtered for quality (QUAL > 10, coverage > 50) and annotated by 812 ATR  ARID1A  BRCA1  BRIP1  CREBBP  EGFR  EP300  ERBB2  FANCA  FAT3  FZD9  KIT  LRP5  MAML1  MLH1  MSH6  NOTCH3  PTEN  ROCK2  TCF7L2  TP53 OC1 
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